Age | The patient’s condition | Treatment | The outcome |
---|---|---|---|
a: 45 y 1 m | The tumor between liver and right diaphragm increased | TCa, 7 cycles | SD |
b: 45 y 9 m | The tumor between liver and right diaphragm increased | Ifosfamide + Doxorubicinb, 3 cycles | PD |
c: 45 y 11 m | The tumor between liver and right diaphragm increased | Proton therapy, 70.2 GyE/26 Fr. For 40 days | PR (Fig. 1) |
d: 46 y 3 m | The tumors outside of the irradiation field remained | Surgery for the left pleural and abdominal tumors | Neuroendocrine carcinoma |
e: 46 y 5 m | Thrombosis in inferior vena cava distal part | An inferior vena cava filter. Discontinued MPAc. | Disappeared 11 months later. |
f: 46 y 5 m | Small disseminations remained at the end of the surgery | dCisplatin + Irinotecan, 4 cycles, every 4 weeks | PD |
g: 46 y 8 m | Liver metastasis increased | Surgery for liver metastasis. | No remnant in surgical field |
h: 46 y 11 m | Effective for small dissemination tumors | dCisplatin + Irinotecan, 2 cycles, every 3 months | Discontinued by dehydration |
i: 47 y 4 m | Multiple lung metastases recurred | TCa, one cycle. | Discontinued by pneumothorax |
j: 47 y 11 m | Abdominal and spleen dissemination increased | Splenectomy and dissemination resection | No remnant in surgical field |
k: 48 y 1 m | Vaginal bleeding by recurrence in vaginal stump | Eribulin 1.4 mg/m2, 3 cycles. | PD |
l: 48 y 4 m | The tumors increased. | TCa, 3 cycles | Hypersensitivity for carboplatin |
m: 48 y 7 m | Discontinuation of carboplatin | Paclitaxel (140 mg/m2) 2 cycles | PD |
n: 48 y 8 m | Jaundice and liver dysfunction | The common bile duct stents (Fig. 2). | Recovered liver dysfunction |
o: 48 y 9 m | Liver metastasis increased | Pazopanib hydrochloride 800 mg/day started | SD to PD (Fig. 2) |
p: 49 y 7 m | Bacterial infection from liver tumor via bile duct | Antibiotics and palliative care | Died with sepsis (Fig. 3) |